L R Silverman

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
    Lewis R Silverman
    Division of Medical Oncology, Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center, Box 1129, One Gustave L Levy Place, New York, NY 10029, USA
    J Clin Oncol 20:2429-40. 2002
  2. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
  3. ncbi request reprint Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia
    Anne Marie O'Farrell
    SUGEN Inc, South San Francisco, CA, USA
    Leuk Res 28:679-89. 2004
  4. ncbi request reprint Clinical roundtable monograph. Overall survival and maintenance of MDS patients
    Lewis R Silverman
    Mount Sinai Medical Center, New York, New York, USA
    Clin Adv Hematol Oncol 7:S3-5. 2009
  5. pmc The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
    Lr Silverman
    Division of Hematology, Mount Sinai School of Medicine, New York, NY, USA
    Ecancermedicalscience 2:118. 2008
  6. pmc Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
    Lewis R Silverman
    Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 117:2697-702. 2011
  7. doi request reprint Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents
    Lewis R Silverman
    Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Leuk Res 33:S18-21. 2009
  8. ncbi request reprint Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
    Lewis R Silverman
    Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Oncol 24:3895-903. 2006
  9. ncbi request reprint The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes
    Lewis R Silverman
    Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Control 11:11-5. 2004
  10. ncbi request reprint DNA methyltransferase inhibitors in myelodysplastic syndrome
    Lewis R Silverman
    Division of Hematology Oncology, Department of Neoplastic Diseases, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1129, New York, NY 10029, USA
    Best Pract Res Clin Haematol 17:585-94. 2004

Research Grants

  1. CANCER AND LEUKEMIA GROUP B--MOUNT SINAI
    Lewis Silverman; Fiscal Year: 2002

Detail Information

Publications14

  1. ncbi request reprint Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
    Lewis R Silverman
    Division of Medical Oncology, Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center, Box 1129, One Gustave L Levy Place, New York, NY 10029, USA
    J Clin Oncol 20:2429-40. 2002
    ..Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS...
  2. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  3. ncbi request reprint Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia
    Anne Marie O'Farrell
    SUGEN Inc, South San Francisco, CA, USA
    Leuk Res 28:679-89. 2004
    ..The translational and clinical analyses described in this report provide some insights into the mechanism and duration of action of SU5416...
  4. ncbi request reprint Clinical roundtable monograph. Overall survival and maintenance of MDS patients
    Lewis R Silverman
    Mount Sinai Medical Center, New York, New York, USA
    Clin Adv Hematol Oncol 7:S3-5. 2009
    ....
  5. pmc The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
    Lr Silverman
    Division of Hematology, Mount Sinai School of Medicine, New York, NY, USA
    Ecancermedicalscience 2:118. 2008
    ..The number of treatment cycles from first response to best response was also measured...
  6. pmc Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
    Lewis R Silverman
    Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 117:2697-702. 2011
    ....
  7. doi request reprint Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents
    Lewis R Silverman
    Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Leuk Res 33:S18-21. 2009
    ..Prolonged survival was independent of achieving complete response. Azacitidine in combination with histone deacetylase inhibitors might offer better efficacy by modulating the methylation and acetylation states of silenced genes...
  8. ncbi request reprint Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
    Lewis R Silverman
    Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Oncol 24:3895-903. 2006
    ..We report the combined results of three previously reported clinical trials (n = 309) with azacitidine using the WHO classification system for MDS and acute myeloid leukemia (AML) and IWG criteria for response...
  9. ncbi request reprint The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes
    Lewis R Silverman
    Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Control 11:11-5. 2004
  10. ncbi request reprint DNA methyltransferase inhibitors in myelodysplastic syndrome
    Lewis R Silverman
    Division of Hematology Oncology, Department of Neoplastic Diseases, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1129, New York, NY 10029, USA
    Best Pract Res Clin Haematol 17:585-94. 2004
    ..Prolonged administration of azacitidine results in reactivation of normal hematopoiesis by its effect on inhibiting DNA methylation...
  11. ncbi request reprint Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS)
    L R Silverman
    Division of Medical Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 6:8-14. 2001
    ..Among the promising new agents are nucleoside analogues, such as 5-azacytidine and decitabine, which reactivate tumor suppressor gene transcription through effects on DNA methylation...
  12. ncbi request reprint Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
    Lewis R Silverman
    Myelodisplastic Syndrome Myeloproliferative Disease Center, Mount Sinai School of Medicine, NewYork, NY, USA
    Nat Clin Pract Oncol 2:S12-23. 2005
    ..g. according to age, risk, classification, and cytogenetic profile), and the combination strategies, particularly with histone deacetylase inhibitors, in the management of MDS...
  13. ncbi request reprint Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 8:2812-9. 2002
    ..The purpose of the study is to investigate the tolerability of interleukin 2 (IL-2) after intensive chemotherapy in elderly acute myeloid leukemia (AML) patients in first complete remission (CR)...
  14. ncbi request reprint Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study
    Alice B Kornblith
    Women s Cancers Program, Dana Farber Cancer Institute, Rm D1210, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 20:2441-52. 2002
    ..The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221)...

Research Grants1

  1. CANCER AND LEUKEMIA GROUP B--MOUNT SINAI
    Lewis Silverman; Fiscal Year: 2002
    ..With these associated investigators in 12 affiliated institutions, Mount Sinai plans to participate in all Group activities. ..